Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia
OncoImmunology , Volume 3 - Issue 12 p. 1- 3
The majority of patients with acute myeloid leukemia (AML) reach complete remission after high-dose chemotherapy. Still, half of these patients experience a relapse due to presence of minimal residual disease (MRD). Here we discuss the poor prognostic role of class II-associated invariant chain peptide (CLIP) expression on residual leukemic cells.